The Latest Breaking News from Merck

Mass layoffs at the Department of Health and Human Services are continuing as the agency makes good on its intention, announced on March 27, 2025, to shrink its workforce by 20,000 people. Among workers dismissed in early April were several teams responsible for fulfilling requests for access to previously unreleased…

Merck & Co. will release its first-quarter earnings later this month, and analysts anticipate a single-digit bottom-line growth.

Trump tariff news: President Trump's latest tariffs took effect Wednesday while China stepped up retaliation. Treasury yields are worrisome. Walmart and Delta Air pulled some guidance, citing tariff uncertainty.

Pharma names whipsawed Wednesday after Trump said he would enact "major" tariffs on drug imports and then backed off his tariffs — for now.

Biotech stocks toppled early Thursday after Trump announced broad global tariffs, including a 20% tariff on goods from Europe.

RFK Jr. was reportedly behind the ouster of FDA’s top vaccine official and said last week that around 10,000 employees will be laid off at the Department of Health and Human Services.

AstraZeneca said Monday its experimental pill lowered "bad" LDL cholesterol by 51%. But AstraZeneca stock fell in line with pharma stocks.

This healthcare company is down more than 30% over the past 52 weeks but still may not be a good buy for value investors.

The FDA is due to make an approval decision on injectable Keytruda by mid-September. The move could bolster downtrodden Merck stock.

Despite Merck’s recent underperformance relative to the S&P 500 Index, Wall Street analysts remain moderately optimistic about the stock’s prospects.

While there are short-term headwinds, Merck has a bright future ahead.